Researchers develop non-invasive method for diagnosis of celiac disease
Spain: Researchers from Spain have developed a non-invasive method that uses saliva for the can help in the diagnosis of celiac disease. The study, published in the journal Cellular and Molecular Gastroenterology and Hepatology, has shown that it is possible to considerably reduce the number of endoscopies that are carried out currently via a non-invasive method of diagnosis. The method...
Spain: Researchers from Spain have developed a non-invasive method that uses saliva for the can help in the diagnosis of celiac disease. The study, published in the journal Cellular and Molecular Gastroenterology and Hepatology, has shown that it is possible to considerably reduce the number of endoscopies that are carried out currently via a non-invasive method of diagnosis.
The method is developed by researchers from Ikerbasque and the UPV/EHU in collaboration with the Biodonostia and Biocruces Institutes and the Txagorritxu and Galdakao Hospitals.
Celiac disease is a complex, autoimmune disorder that affects genetically susceptible individuals. It is estimated that 1% of the population suffer from this disease. To be able to diagnose celiac disease it is necessary at present to carry out an endoscopy, a test that is not only highly unpleasant, but also costly and in some cases unnecessary. Patients with symptoms of celiac disease undergo an endoscopy, but the symptoms, such as stomach pain, weight loss or anemia, are very common and are similar to those of other disorders of the digestive system. In turn, the genetic variant conferring an increased risk of developing celiac disease is present in a high percentage of the healthy population. So many non-celiac patients with symptoms and who are at a genetic risk are needlessly subjected to an endoscopy.
This was the procedure they followed: firstly, they confirmed that the same inflammation seen in the intestine of celiac patients could be detected in saliva. The inflammation was then quantified in saliva samples from celiac and control patients. These saliva samples were also tested for the genetic risk of developing celiac disease. With these data on inflammation and genetic risk, a predictive formula was developed. The predictive capacity of this model was subjected to a blind test involving 100 saliva samples, and that resulted in a 73% success rate. In addition, the predictive model displayed a sensitivity of 91%, signifying a 91% success rate among people with celiac disease.
Ainara Castellanos, the lead researcher of the study, and Maialen Sebastian, a pre-doctoral student, consider that the method they have developed "is very useful for screening patients with suspected celiac disease before endoscopy is carried out". They also recognized that, despite the good results obtained with their prediction model, it is not 100% accurate, which means that the current traditional diagnostic method cannot be totally ruled out. So the authors of this study propose that only those individuals predicted by this model to have celiac disease should undergo an endoscopy, which would considerably reduce the number of endoscopies currently performed.
They also showed that the same saliva sample can also be used to test for the genetic risk of the disease, so it could also offer a non-invasive alternative to genetic testing using blood samples, given that the collecting of saliva samples is more convenient than blood collection.
Reference:
The research letter titled, "A Novel Noninvasive Method Based on Salivary Inflammatory Biomarkers for the Screening of Celiac Disease," is published in the journal Cellular and Molecular Gastroenterology and Hepatology.
DOI: https://www.sciencedirect.com/science/article/pii/S2352345X21001107
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd